$AEMD Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical (AEMD), is focused on discovering exosomal biomarkers to diagnose and monitor Alzheimer's disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Our TauSome™ biomarker (also referred to as exosomal tau) is being studied as the basis for a blood-based test to identify CTE through the DETECT Study being conducted by the Boston University CTE Center. TauSome™ detection and the use of a TauSome™ biomarker to identify and monitor CTE and other neurological disorders are protected by multiple patent applications. #CTE
Visit www.exosomesciences.com for additional details.
http://stockpumpers.blogspot.com/2016/02/aeth...ences.html
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!